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Abstract
Objective: To explore the usefulness of the Portuguese HADS for outpatients with focal epilepsy. Methods: Ninety-nine
outpatients were assessed using a socio-demographic and clinical questionnaire, the MHI-5, and the HADS (individual
interview).Results: HADS proved to be understandable and well accepted by patients, with alpha ranges from 0.72 to 0.82. It
also correlated with MHI-5 and some demographic and clinical variables.Conclusions: The results support the use of the
Portuguese HADS as a screening tool for these patients (facial validity; internal consistency; construct validity), though the
associations between HADS scores and some demographic and clinical variables question its validity. The results underscore
the importance of assessing patient affective status, as anxiety and depression are common and provide additional insight into
the association of anxiety/depression with certain demographic and clinical variables. The reasons for the inconsistencies
between these results and published literature should be explored in future studies.
The work was done at Neurophysiology Department -
Hospital Geral de Santo António, Porto, Portugal.
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INTRODUCTION
ANXIETY AND DEPRESSION IN (FOCAL)
EPILEPSY
Interictal anxiety, can affect as high as 66% of those with
epilepsy, can be a reaction to the possibility of having a
seizure or to the interferences of epilepsy on daily life ( 1 , 2
). Moreover, psychiatric and neuropsychological factors can
interact, making patients daily functioning even more
difficult ( 3 ). Since affective state can influence performance
in tasks used to assess other functional potentialities and
limitations, affective assessment is essential ( 4 , 5 ) and can
help optimize care. In fact, in Portugal, patients with
epilepsy reported a need for specialized support to cope with
several psychosocial issues, namely related to specific
emotional worries ( 6 ).
Psychiatric symptoms are common in epilepsy patients ( 7 , 8
). Even though the majority of those with well controlled
epilepsy do not show significant evidence of
psychopathology, some (especially those with chronic
epilepsy) present serious psychiatric disorders ( 9 ). The
additional burden of having a co-morbid mental disorder
seems to be significant for individuals with chronic epilepsy
( 9 ). Furthermore, psychiatric symptoms can develop in
relation to the seizures, but they are usually present as an
interictal chronic condition ( 2 ). As depression and anxiety
seem to be among the most common co-morbidities of
epilepsy ( 9 , 10 , 11 , 12 , 13 , 14 ), it is also crucial to consider
them in epilepsy research, since any of these disorders may
bias other clinical indicators and/or research variables: e.g.,
several perceptions and performances (cf. 15 ).
Unfortunately, psychopathological symptoms are not
regularly diagnosed, nor treated, in epilepsy patients,
perhaps because health care professionals do not have
enough time to do so ( 9 , 16 , 17 , 18 , 19 , 20 ). For example,
O’Donoghue et al. ( 21 ) found that among individuals with
one or more epileptic seizures, only a third of those
classified as “definite or possible cases” according to the
Hospital Anxiety and Depression Scale (HADS) had records
of psychological symptoms in their clinical records of the
previous two years. Thus, treatment and prevention of co-
morbid psychiatric disorders require instruments that do not
disrupt the clinical routine. The HADS seems a very good
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candidate for such a role as far as anxiety and depression are
concerned, with promising results reported in the literature.
The HADS showed no differences in anxiety between
individuals with and without (partial) epilepsy ( 22 , 23 ). On
the other hand, in patients with other somatic diseases,
including epilepsy, and post-natal women, the prevalence of
anxiety symptoms, according to the HADS, was 11-22% ( 20
). The same scale indicated that the prevalence of anxiety
symptoms in patients with partial epilepsy was: none = 52%,
mild = 25%, moderate = 16%, and severe = 7% ( 24 ).
The HADS also revealed signs of anxiety in over 40% of
individuals with recently diagnosed epilepsy, without serious
psychological or medical diseases ( 25 ). In these individuals,
the HADS also indicated that being younger, being a
woman, and having more recent seizures is significantly
associated with higher scores of anxiety, but not depression (
25 ). The anxiety score from the HADS correlated with
seizure frequency, epilepsy duration, and sex in individuals
taking antiepileptic medication ( 26 ). Sex was also an
important factor explaining the variability of anxiety –
women were more likely to be anxious than men ( 26 ).
In outpatients with newly diagnosed and chronic epilepsy,
only the type of epilepsy was significantly associated with
the State-Trait Anxiety Inventory-State index, whereas high
seizure frequency, polypharmacy, symptomatic focal
epilepsy, and female gender were positively correlated with
the State-Trait Anxiety Inventory-Trait index ( 27 ).
In adults with epilepsy in the community, the prevalence of
anxiety (HADS) was 20.5% (95% CI: 16.9-24.1%). It was
associated with a current history of depression, perceived
side effects of antiepileptic medication, lower educational
attainment, chronic ill health, female gender, and
unemployment. It was not associated with the duration of
epilepsy ( 28 ).
With regard to depression, the HADS showed no differences
between individuals with and without (partial) epilepsy ( 22 ,
23 ). According to the same scale, the prevalence of
depressive symptoms in patients with somatic diseases,
namely epilepsy, and post-natal women was 11-19% ( 20 ). In
a sample of patients with partial epilepsy, the HADS
indicated a prevalence of: none = 62%,, mild = 20%,,
moderate = 14%, and severe = 4% ( 24 ).
The HADS indicated signs of depression in more than 15%
of subjects with recently diagnosed epilepsy ( 25 ). It also
revealed that in individuals taking antiepileptic medication,
depression correlated with seizure frequency, epilepsy
duration, age at seizure onset, and age ( 26 ).
The prevalence of depression (HADS) in a nonspecialist
care-identified epilepsy population was 11.2% (95% CI:
8.3-13.7%), i.e., greater than in the general population ( 29 ).
Depression was most strongly associated with
unemployment, but also with having had a recent seizure and
perceived medication side effects ( 29 ). It was not associated
with gender, marital status, monotherapy or polytherapy ( 29
). In epilepsy outpatients, high seizure frequency, type of
epilepsy syndrome and a high number of antiepileptic drugs
(AEDs) were significantly and positively associated with
depression (Beck Depression Inventory-21), while female
gender showed a trend towards being significantly
associated with depression ( 27 ).
The HADS indicated that in patients with somatic diseases,
including epilepsy, and post-natal women, about half had co-
morbid depressive and anxiety symptoms ( 20 ). In patients
with temporal lobe epilepsy, depression and anxiety (Beck
Depression Inventory and Self-Rating Anxiety Scale) were
related to type of intervention (epilepsy surgery + AEDs or
AEDs alone), underlying epileptogenic lesion, change of
seizure control and AED ( 30 ). The authors concluded that
depression improved not because of surgery, but because of
improved seizure control ( 30 ).
Maybe methodological differences explain the inconsistency
of the complex relationship verified between epilepsy
variables (e.g., seizure frequency and type, epileptogenic
focus laterality) and depression ( 14 ). Nonetheless, there
seem to be higher depression levels in individuals with
temporal lobe epilepsy or psychomotor vs. generalized
seizures ( 14 ).
In summary, research shows that anxiety and depression are
associated with and predict important variables, including
epilepsy patients’ quality of life ( 24 , 31 , 32 , 33 , 34 , 35 ).
Therefore, psychological treatment of negative affect may
improve patients’ quality of life ( 36 ).
ANXIETY, DEPRESSION, AND ITS
ASSESSMENT: THE HADS
The detailed psychometric properties of the instrument(s)
chosen for a particular study or intervention focusing on
anxiety and/or depression are rarely adequately reported,
which is surprising when the literature shows a wide
variation in terms of scale construction and composition ( 37
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The HADS has some remarkable characteristics: a) it has
been translated to a number of languages, and is widely
used, in several cultures, with numerous populations, of
various age groups, and purposes (cross-sectional and
longitudinal studies); b) it is short and easy/quick to
administer (2-6 minutes) and score; c) it is a self-report
scale; d) it separates anxiety from depression; e) it
emphasises anhedonia; f) it avoids symptoms likely to
appear in somatic diseases (e.g., weight loss); g) it is easily
understandable and accepted by patients, since it does not
cover serious psychopathologic symptoms (also avoids floor
effects); h) it has potential as a screening tool, providing
scores suggestive of the probability of anxiety/depression, as
well as its levels; i) it provides ranges suggestive of the
disorder severity; j) it provides a record of longitudinal data;
k) it has satisfactory psychometric properties, namely face
validity; and l) since the scores are influenced by the
intervention, it can give some therapeutic guidance ( 38 , 39 , 40
, 41 , 42 , 43 , 44 , 45 ). It is able to predict mood over a year or
more, compliance, quality of life, 1-year mortality (HADS-
Depression) and physical symptoms (HADS-Anxiety) ( 40 , 46
).
The HADS was developed based on data gathered from
individuals aged 16 to 65 years, men and women, with a
variety of physical pathologies/complaints, and from
hospital staff ( 47 ). The HADS, developed for non-
psychiatric hospital use, adequately reached its goal: to
assess psychological states with a minimum of disturbance
due to somatic disease symptoms ( 41 , 45 , 47 ). Its subsequent
use showed that it is a useful and reliable measure to screen
for clinically significant anxiety and depression; and that it is
a valid measure of the severity of these conditions ( 45 , 47 ). It
can also be used with adolescents between 12 and 17 years
of age ( 48 ).
Consequently, this primarily clinical tool is also widely used
in clinical research ( 37 , 44 , 49 ). It is worth stressing that the
HADS does not aim at providing psychiatric diagnosis, but
to emphasise the separation between anxious and depressive
states ( 44 ). In clinical settings, high scores should be
followed by an in-depth psychiatric interview ( 40 ).
The HADS focuses on the generalized anxiety state and not
necessarily on the anxiety for a specific situation (e.g,
hospital visit); it covers the anxious state, restlessness and
anxious thoughts ( 44 , 45 ). The HADS-Anxiety is mainly
constituted by mood, followed by behaviour and, finally,
cognition, ignoring the arousal and somatic aspects; the
HADS-Depression focus on the loss of pleasure, i.e., mainly
in the loss of interest and diminished pleasure response
(anhedonia – 85.7% - and fatigue – 14.3%) ( 37 , 42 , 44 , 45 , 47 ,
49 ).
The HADS refers to the previous week ( 45 , 47 ). It comprises
14 multiple-choice items, equally divided by two subscales
(Anxiety and Depression), with independent scoring ( 45 ).
Unlike typical state instruments, it is sufficiently stable to
resist to situational influences, but it is less stable than
typical trace scales, in a broader time period ( 40 ).
Even though the HADS authors and some research data do
not recommend the use of a global score ( 40 , 44 , 45 , 47 ),
there is also data supporting the use of three scores (global,
anxiety, and depression) ( 15 , 41 ). Moreover, research shows
that the HADS allows the separate assessment of anxiety and
depression, but there is some overlap, mainly due to an
actual overlap of symptoms ( 40 ). In fact, some data support
the existence of common factors/dimensions shared by
anxiety and depression ( 50 ).
As each item is answered on a 4-point scale (0 – 3), possible
scores range from 0 to 21 (anxiety/depression) and 0-42
(negative affect ( 15 )). In the absence of consensus ( 38 , 51 , 52
), scores are usually interpreted as: 0-7 normal, 8-10 low,
11-14 moderate, and 15-21 severe for anxiety or depression (
43 , 45 ). The validation process of the Portuguese HADS
version shows psychometric properties similar to those in
international studies ( 53 ).
Research and clinical practice underscore that there is still
much to be done and to study to adequately assess,
understand, prevent, and treat psychiatric co-morbidity in
epilepsy ( 9 , 50 ). Routine affective assessment and the
consideration of its relevance for the general presentation
should be included in every clinical assessment ( 54 ). Being
so, the aim of the present study was to explore the usefulness
of the HADS-Portuguese version as a screening instrument
and, consequently, intervention aid for Portuguese
outpatients with focal epilepsy.
METHOD
A consecutive sample of 99 outpatients with clinical
evidence of focal epilepsy, from the Epilepsy Unit of
Hospital Geral de Santo António (Porto, Portugal), was
assessed. More than half were women, married/cohabiting,
and professionally active (cf. Table 1), even though there
was a considerable variability in terms of profession. The
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sample also varied greatly in terms of age (14-70 yrs) and
schooling (0-17 yrs; cf. Table 1).
Figure 1
Table 1: Socio-demographic Characteristics of the
Participants (=99)
In clinical terms, the majority of participants: were on
monotherapy with AEDs, had normal AED serum levels,
reported no side-effects, had done an electroencephalogram
(EEG) and a CT (computerized tomography) scan
previously, had done no MRI (magnetic resonance imaging),
had no lesional epileptic focus, had the last seizure more
than a month before assessment, had a single seizure type,
and had one or less than one seizure a month (cf. Table 2).
The sample encompasses individuals with very diverse
disease onset (M (97)=15.59, SD=10.91, 0.17-46.00 yrs) and
age at disease onset (M (97)=20.70, SD=13.39, 0-57 yrs).
The most frequently used AEDs were: phenytoin, valproic
acid, carbamazepine, clobazam, and primidone.
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Figure 2
Table 2: Clinical Characteristics of the Participants (=99)
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A socio-demographic and clinical questionnaire, the Mental
Health Questionnaire-5 (MHI-5), and the HADS were
administered in the context of an individual interview, due to
the expected low literacy of some participants. Some clinical
data was obtained from the patients’ physicians, through the
consultation of their medical records. Internationally
accepted ethical standards were followed, namely adherence
to the ethical principles of the Declaration of Helsinki (for a
detailed report of the procedure, see Meneses ( 15 )).
The Portuguese version of the MHI-5 has a structure similar
to the original version, making it possible to use it in a
similar way ( 55 ). It has five items representing four
dimensions of mental health (Anxiety, Depression, Lost of
Control Emotional-Behavioural, and Psychological Well-
being), so three items are from the Distress Scale and two
from the Positive Well-being Scale of the MHI; it can be
used independently, as a screening instrument, or included in
other scales (e.g., SF-36); research has shown its utility as a
screening instrument ( 55 ). It is scored with higher scores
indicating a better health state ( 56 ).
It is worth stressing that the MHI-5 was chosen as a marker
for the HADS construct validity because the MHI-5 is brief,
is frequently used worldwide in health care settings, namely
as part of the SF-36 ( 15 ), and has been proved useful as a
screening instrument. Nevertheless, unlike a psychiatric
interview (especially one guided by a validated scale), the
MHI-5 is not considered a gold standard instrument
regarding the HADS capacity to identify symptoms of
anxiety and/or depression. When using the MHI-5 as a
validity marker regarding screening per se, one should
remember that the MHI-5 and the HADS are built with
different construct aspects (cf. what was previously said
about both instruments).
RESULTS
Table 3 shows the minimum, maximum, mean, and
standard-deviation values obtained by the participants in the
HADS and MHI-5 (sub)scales and items. It also shows the
internal consistency of each (sub)scale (Cronbach alpha).
Consequently, it demonstrates there was considerable
variability in the sample as far as these mental health
indicators were concerned. It also indicates that the internal
consistency of the (sub)scales can be considered from
acceptable (>0.70) to good (>0.80).
Figure 3
Table 3: Minimum, Maximum, Mean, Standard-deviation,
by Item and Scale, and Internal Consistency (Cronbach
Alpha) of each Scale (=99)
Table 4 illustrates a more important clinical indicator of the
sample, considering the most recent cut-off values of the
English language version of the HADS ( 43 , 45 ). It shows a
significant number of cases of anxiety or depression, mostly
anxiety, according to the HADS.
Figure 4
Table 4: Frequencies and Percentages of Participants in the
Different Severity Classes of the HADS (=99)
Table 5a and 5b show the correlations between HADS and
MHI-5 items and scores obtained by the participants. Of all
the possible correlations, only 11 were not statistically
significant: 10 between HADS and MHI-5 items and one
between item 11 of the HADS and HADS-Depression.
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Figure 5
Table 5a: Correlations (2-tailed) Between HADS and MHI-5
Items and Scores (=99)
Figure 6
Table 5b: Correlations (2-tailed) Between HADS and MHI-5
Items and Scores (=99) (Continued)
With regard to the relationship between HADS and MHI-5
and the socio-demographic characteristics of the sample,
there was no statistically significant correlation between: a)
HADS-Anxiety and age, or schooling; b) HADS-Depression
and schooling; c) HADS-Total and age, or schooling; and d)
MHI-5 and schooling. HADS-Depression (r(99)=0.22,
p=0.03) and MHI-5 correlated with age (r(99)=-0.20,
p=0.04). Only one item (item 12) of the HADS correlated
with age (r(99)=0.20, p<0.05); while two others correlated
with schooling (item 11 - r(99)=-0.35, p<0.001 - and 14 -
r(99)=-0.25, p<0.01).
There were statistically significant differences between men
and women in some HADS items (1, 3, 7, 9, 10, and 13),
HADS-Anxiety, HADS-Depression, HADS-Total, and
MHI-5 (cf. Table 6). Women always had higher scores than
men in these HADS indicators. For MHI-5, men reported
better mental health.
Figure 7
Table 6: Differences between Men and Women in HADS
Items and Scores and in MHI-5 (2-tailed)
There were no statistically significant differences between
married/cohabiting and single participants for HADS-
Anxiety, HADS-Total, or MHI-5. With regard to HADS-
Depression, the 62 married participants (M=5.76) had a
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statistically significant higher mean than the 32 single ones
(M=3.94; t(86.230)=2.282, p=0.03). As far as HADS items ,
married participants had a statistically higher mean for item
5 (M=1.73) than single participants (M=1.28, t(92)=2.033,
p=0.045).
There were no statistically significant differences between
those professionally active (n=67) and those inactive (n=32)
for HADS-Anxiety, HADS-Depression, HADS-Total, and
MHI-5. Item 14 differentiated professionally active from
professionally inactive participants: active ones had a
statistically higher mean (M=0.99 vs. M=0.44,
t(87.592)=2.804, p=0.006).
With regard to clinical variables, there were no statistically
significant correlations between any HADS item or score
and disease onset. There was also no correlation between
HADS-Anxiety and age at disease onset. MHI-5 did not
correlate with disease onset or age at disease onset. HADS-
Depression (r(97)=0.21, p=0.04), HADS-Total (r(97)=0.23,
p=0.02), item 1 (r(97)=0.20, p<0.05), item 4 (r(97)=0.23,
p=0.02), and item 11 (r(97)=0.29, p=0.005) correlated with
age at disease onset.
There were no statistically significant differences between
subjects on monotherapy (n=53) and taking more than one
AED (n=38) with regard to HADS-Anxiety, HADS-
Depression, HADS-Total, or any HADS item. Those on
monotherapy (M=20.74) had better mental health than those
on polytherapy (M=18.08, t(89)=2.094, p=0.04).
There were no statistically significant differences between
those who had the last seizure less than a month before
assessment and those who had it more than a month before
assessment in HADS-Anxiety. Those who had the last
seizure less than a month before assessment had a
statistically higher HADS-Depression mean, HADS-Total
mean, and a statistically higher mean in items 4, 5, 6, 7, 8,
12, and 14 than those who had it more than a month before
assessment. Those with a more recent seizure also had worse
(lower) mental health according to the MHI-5 (cf. Table 7).
Figure 8
Table 7: Differences between Participants with a More or
Less Recent Last Seizure in HADS Items and Scores and in
MHI-5 (2-tailed)
There were no statistically significant differences between
those who had one seizure type (n=67) and those who had
more than one seizure type (n=29) in terms of HADS-
Anxiety, HADS-Depression, HADS-Total, or MHI-5.
Nevertheless, they differed in items 3 and 5 of the HADS:
those with more than one seizure type had a higher mean on
item 3 (M=1.59 vs. M=0.94, t(94)=2.701, p=0.008) and 5
(M=2.14 vs. M=1.42, t(94)=3.315, p<0.001).
There were no statistically significant differences between
subjects with more (daily to <= 1/month, n=40) or less
frequent (n=47) seizures in terms of HADS-Anxiety, HADS-
Depression, HADS-Total, or in any HADS item.
Nevertheless, according to MHI-5, individuals with more
frequent seizures (M=18.03) had worse mental health
(M=21.32, t(85)=2.684, p=0.009).
There were no statistically significant differences between
those who had a lesional epileptic focus (n=35) and those
who did not (n=49) on MHI-5 or any HADS item or score,
except for item 14, in which those who had a lesional
epileptic focus had a higher mean (M=1.11 vs. M=0.61,
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t(82)=2.200, p=0.03).
DISCUSSION
The present cross-sectional study investigated the usefulness
of the HADS-Portuguese version as a screening instrument
for Portuguese outpatients with focal epilepsy. To do so, the
HADS was compared with another, briefer and widely used,
screening instrument, the MHI-5, namely through the
analysis of the relationships between HADS vs. MHI-5
indicators and several demographic and clinical variables.
The results indicate that the Portuguese HADS (and MHI-5)
is understandable and well accepted by outpatients with
clinical evidence of focal epilepsy and a wide age and
schooling range, independent of their sex, marital and
professional status, and disease characteristics. In fact, the
sample is quite heterogeneous demographically and
clinically. For instance, even though the sample, as a whole,
can be considered a sample of individuals with clinical
evidence of moderate severity focal epilepsy, it encompasses
individuals with indicators of considerable severity (e.g.,
more than a seizure type, frequent seizures, polytherapy,
toxic AED serum levels).
More specifically, the absence of statistically significant
correlations between HADS and MHI-5 and schooling
supports their use regardless of the respondents’ formal
education. However, it should be pointed out that, in the
present study, the instruments were not self-administered.
Regarding the comparison between HADS and MHI-5, the
first interesting finding concerns their internal consistency,
which is the same for both scales and a good one (cf. Table
3). Additionally, participants of the study answered to both
scales’ items using the full range of response choices.
Even though the MHI-5 has a “positive” component (two of
its items are from the Positive Well-being Scale of the MHI)
and some HADS items are also “positive” (e.g., item 4), only
the HADS offers the possibility of classifying respondents
into severity classes, an important indicator in clinical and
research settings (cf. Table 4). In this context, it is necessary
to emphasize an important factor: there are Portuguese
norms for the SF-36 version 1 ( 57 ), which includes the
MHI-5, and there are still no such norms for the Portuguese
HADS.
Concerning the relationship between HADS and MHI-5
items and scores, it is worth stressing that of all the 157
possible correlations, only 11 were not statistically
significant (cf. Table 5). These exceptions should be
analyzed. First, the non-significant correlation between item
11 of the HADS and item 3 of the MHI-5 is not in the
expected direction. Second, item 11 of the HADS also does
not present a statistically significant correlation with items 1,
2, and 5 of the MHI-5, i.e., it only correlates with item 4.
Third, this is also the only HADS item that does not
correlate with all HADS scores (namely, HADS-
Depression). Consequently, these results question the
adequacy of item 11.
Furthermore, item 1 of the MHI-5 does not correlate with 4
HADS items (2, 4, 8, and 11), item 3 of the MHI-5 does not
correlate with items 2, 11, and 14 of the HADS, and item 5
of the MHI-5 does not correlate with items 10 and 11 of the
HADS. Therefore, these results offer some evidence that the
items of the two scales are not assessing (exactly) the same
construct(s). In fact, as was stressed previously, MHI-5 and
HADS are built with different construct aspects. Even so, it
is worth noticing that the MHI-5 global score correlates
more strongly with HADS-Total than with HADS-Anxiety
or Depression, giving some support to the use of HADS-
Total as a index of mental health/negative affect ( 15 , 41 ).
Another relevant set of findings concerns the association
patterns between HADS/MHI-5 and demographic and/or
clinical variables. Again, these patterns reflect the fact that
MHI-5 and HADS are built with different construct aspects.
In fact, MHI-5 correlated with age, as did HADS-
Depression, but not HADS-Total nor HADS-Anxiety. One
should also be aware of the insensitivity of MHI-5 to disease
onset and age at disease onset, while HADS-Depression and
HADS-Total correlated with age at disease onset, an
important finding in terms of mental health prevention. In
addition, HADS-Depression was the only indicator sensitive
to marital status.
Inversely, MHI-5 showed that those on monotherapy had
better mental health than those on polytherapy, which makes
perfect sense, especially when one considers that
polytherapy is usually associated with more severe epilepsy.
Strangely, no HADS item or score pointed in the same
direction.
The results regarding the last seizure also question the
consistency of the scores obtained. In fact, there were no
statistically significant differences between those who had
the last seizure less than a month before assessment and
those who had it more than a month before assessment in
HADS-Anxiety, but those with a more recent seizure
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reported worse mental health according to the MHI-5 and
HADS-Total, and more depression. Another unforeseen
discrepancy relates to seizure frequency: HADS scores and
items were not sensitive to seizure frequency and MHI-5
was (in the expected direction).
Still, not all association patterns differed. Indeed, regarding
sex differences, there was consistency between HADS and
MHI-5 scores. Additionally, MHI-5 and HADS scores were
both not sensitive to professional status, seizure types, and
lesional epileptic focus status.
Even though all statistically significant associations
(correlations or differences) between HADS items and
demographic/clinical variables made clinical sense and/or
were in the expected direction considering the scientific
literature, the fact that there were incongruities between
items’ associations and scores’ associations calls for
reflection. Actually, one can hypothesize that the
information lost when aggregating items, namely by
ignoring some items ability to discriminate between certain
groups of patients, may be clinically relevant. For instance,
the type of anxiety symptoms a patient experiences (assessed
by a self-report scale as the ones used) can be an important
aid in planning the best possible intervention. Consequently,
the HADS, with its 7+7 items, allows for the systematization
and analysis of some clinically relevant aspects a briefer
instrument, such as the MHI-5, does not.
In general, the present results showed that: (a) the internal
consistency of the HADS was comparable to those reported
in the literature ( 38 , 45 ); b) its face validity seemed
appropriate ( 45 ); and c) its construct validity (considering
the MHI-5) acceptable. Nonetheless, the associations
between HADS scores and some demographic and clinical
variables questions its construct validity. In fact, it is
important to note that the instrument didn’t correlate with
some demographic and clinical variables known to influence
depression and anxiety.
This study aimed to explore the usefulness of the HADS not
only as a screening instrument, but also as an intervention
aid for Portuguese outpatients with focal epilepsy. In this
context, the raw scores and the relationships found between
HADS scores and the participants’ demographic and clinical
characteristics are worth analysing (the latter also as markers
of the instrument construct validity). In fact, the raw scores
suggest that anxiety and depression are common
psychological disorders in focal epilepsy (cf. Table 4), which
is in accordance with previous studies ( 1 , 2 , 8 , 9 , 20 , 24 , 27 ,
28 , 29 , 38 ). The results also showed there are several
demographic and clinical characteristics associated with
these disorders. In the sample studied, anxiety (more
frequent) was associated with sex (women worse),
replicating previous findings ( 27 , 28 , 37 , 38 ).
Still, in the same sample, anxiety was not associated with:
age, schooling, marital status, professional status, age at
disease onset, disease onset ( 28 ), type of therapy, last seizure
recency, seizure types, seizure frequency, or lesional
epileptic focus status. These results differ from those of
Mensah et al. ( 28 ) (educational attainment, unemployment),
Jacoby et al. ( 26 ) (seizure frequency, disease onset/epilepsy
duration), Ridsdale et al. ( 25 ) (age, having more recent
seizures), Reuber et al. ( 30 ) (underlying epileptogenic
lesion, AED therapy), and Kimiskidis et al. ( 27 ) (seizure
frequency, type of therapy/polypharmacy).
Depression, on the other hand, was associated with: age
(older worse), sex (women worse), marital status (married
worse than single), age at disease onset (older worse), and
last seizure recency (more recent worse). These results agree
with those from Jacoby et al. ( 26 ) as far as age and age at
seizure onset are concerned. Similarly, Kimiskidis et al. ( 27 )
found that female gender showed a trend towards being
significantly associated with depression. Still, Mensah et al.
( 29 ) found that depression was not associated with sex or
marital status, but it was associated with having had a recent
seizure.
Inversely, in the present sample, depression was not
associated with: schooling, professional status, disease onset,
type of therapy, seizure types, seizure frequency, or lesional
epileptic focus status. These results are not in accordance
with those of Jacoby et al. ( 26 ) (seizure frequency, disease
onset/epilepsy duration), or Kimiskidis et al. ( 27 ) (seizure
frequency, high number of AED/type of therapy). Similarly,
Ridsdale et al. ( 25 ) found that being younger, woman, and
having more recent seizures is not significantly associated
with higher scores of depression. Mensah et al. ( 29 ) found
that depression was not associated with monotherapy or
polytherapy, but it was associated with unemployment.
Reuber et al. ( 30 ) found that depression related to underlying
epileptogenic lesion, and AED therapy.
Finally, negative affect (HADS-Total) was associated with:
sex (women worse), age at disease onset (older worse), and
last seizure recency (more recent worse). Nevertheless, in
the same sample, negative affect was not associated with:
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age, schooling, marital status, professional status, disease
onset, type of therapy, seizure types, seizure frequency, or
lesional epileptic focus status.
It should be noted that no HADS item or score showed
statistically significant differences between those on
monotherapy and those on polytherapy (generally, a sign of
more severe epilepsy). The fact that 28 out of the 38
individuals on polytherapy were on 2 AED does not seem
sufficient to understand this unexpected result. The reasons
for this and other inconsistencies between the present results
and some of the published literature should be explored in
future studies.
For now, one can assume the differences in the sample
demographics and/or clinical characteristics and in
methodology account for some of the differences between
the studies. Be as it may, these contradictions should alert
clinicians not to automatically generalize research findings
to their patients, stressing the importance of assessing each
patient’s affective status.
To optimize the use of the Portuguese HADS with focal
epilepsy patients, it would be important to be familiar with
the response patterns of Portuguese individuals, especially
with focal epilepsy, to the HADS considering the
demographic variables included in the present study ( 25 , 26 ,
40 ). Additionally, it would be important to know if HADS
scores vary during the natural course of (focal) epilepsy ( 21 ,
22 , 23 , 25 , 26 ). It is also of the upmost importance to clarify
the processes underlying the anxiety and depression scores
reported by different epilepsy samples ( 1 , 2 , 3 , 7 , 11 , 12 , 14 )
and to identify the prevalence of the different types of
anxiety and/or depression (pre, post, inter, ictal, with no
relation to seizures), since they differ regarding the
underlying pathophysiological mechanisms ( 1 , 2 , 3 , 7 , 14 , 18
, 27 ).
In conclusion, even though the present results suggest that
the HADS should be more thoroughly studied, they support
the use of the Portuguese HADS as a screening tool to be
used with focal epilepsy patients. It seems that its routine use
could help optimize health care and control for some biases
in research, without consuming much time, a key factor in
health care. Considering that the HADS should not be used
as a diagnostic tool, its substitution for the MHI-5 as a
screening tool of mental health could be considered
acceptable, especially in situations in which time constraints
are crucial. Nevertheless, this substitution leads to a
considerable loss of information and specificity that has to
be carefully weighted. The time frame of interest is another
important variable, since the two instruments refer to
different periods of time. Above all, the results underscore
the importance of assessing patient affective status, since
anxiety and depression are common in focal epilepsy
outpatients and provide additional insight to the association
of anxiety and depression with certain demographic and
clinical variables.
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